Sensus Healthcare Reports Second Quarter

Sensus Healthcare Reports Second Quarter

2019 Financial Results

BOCA RATON, Fla. (August 8, 2019) -

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive

and cost-effective treatments for both oncological and non-oncological conditions, announces financial results for the three and

six months ended June 30, 2019.

Highlights from the second quarter of 2019

and recent weeks include:

Management Commentary

"As anticipated, second quarter financial

results mark a return to double-digit revenue growth highlighted by sales of our feature-rich SRT-100 Vision system," said

Joe Sardano, Sensus Healthcare's chairman and chief executive officer. "The issue underlying our decision during the

first quarter to moderate SRT-100 Vision sales to a key customer has been resolved to our satisfaction, including contract renewal,

and we began in the second quarter to ship the systems we held back. Included in the 17 SRT-100 Vision units sold during the second

quarter is a sale to Shaare Zedek Medical Center in Jerusalem, our fourth Vision customer in Israel. We are focused on broadening

our customer base to large practices and hospital centers, and these efforts are beginning to show results.

"We continue to invest in sales and

marketing, and exhibited our SRT systems for the treatment of keloids and non-melanoma skin cancer at several regional dermatology

trade shows. In recent weeks, our SRT-100+ was featured on a popular dermatology cable TV program, where a young woman's keloids

were treated successfully. The show is hosted by Dr. Sandra Lee, and we look forward to continued exposure for SRT to treat keloids,

particularly given a recent clinical study showing just a 3% recurrence rate after surgery and SRT. In June we exhibited our Sculptura

Modulated Robotic Brachytherapy with Beam Sculpting capabilities and Robotic Respiratory Tracking at the 2019 American Brachytherapy

Society's Annual Meeting. We are pleased with the work of our oncology team and the interest being generated in this recently

approved product," Mr. Sardano continued.

"Our Sculptura collaboration with

the Perelman School of Medicine at the University of Pennsylvania began during the second quarter. We anticipate several more Sculptura

collaborations with prominent medical schools later this year.

"Looking forward to the second half

of 2019, we anticipate double-digit revenue growth driven by sales of the SRT-100 Vision to the dermatology and oncology markets.

Second Quarter Financial Results

Revenues for the second quarter of 2019

were $7.5 million, an increase of 23% over $6.1 million for the second quarter of 2018. The increase was attributable to increased

sales of the higher-priced SRT-100 Vision product.

Gross profit for the second quarter of

2019 was $4.9 million, or 66.1% of revenues, compared with $3.9 million, or 65.1 % of revenues, for the second quarter of 2018.

The increase in gross margin was mainly due to a shift in product mix favoring higher margin SRT-100 Vision units.

Selling and marketing expense for the second

quarter of 2019 was $2.0 million, unchanged from the second quarter of 2018.

General and administrative expense for

the second quarter of 2019 was $0.96 million, compared with $0.91 million for the second quarter of 2018.

Research and development expense for the

second quarter of 2019 was $1.9 million, compared with $1.6 million for the second quarter of 2018. The increase was mainly due

to expenses related to the ramp-up to production of the Sculptura.

Net income for the second quarter of 2019

was $0.1 million, or $0.01 per diluted share, compared with a net loss of $(0.5) million, or $(0.04) per share, for the second

Adjusted EBITDA for the second quarter

of 2019 was $0.4 million, compared with $(0.2) million for the second quarter of 2018. Adjusted EBITDA is defined as earnings before

interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP

and non-GAAP financial measures, and the specific reasons these non-GAAP financial measures are provided.

Cash and investments were $16.8 million

as of June 30, 2019, compared with $15.4 million as of December 31, 2018. The company had no long-term debt and no outstanding

borrowings on its revolving line of credit as of June 30, 2019.

Six Month Financial Results

Revenues for the first half of 2019 increased

7.5% to $12.9 million, compared with $12.0 million for the first half of 2018. Gross profit for the first half of 2019 was $8.3

million, or 63.9% of revenue, compared with $7.9 million, or 65.6% of revenue, for the first half of 2018.

Selling and marketing expense was $4.5

million for the first half of 2019, compared with $4.2 million for the first half of 2018. General and administrative expense was

$2.0 million year-to-date, compared with $2.3 million for the prior-year period. Research and development expense for the first

half of 2019 was $3.9 million, compared with $3.1 million for the first half of 2018.

The net loss for the first half of 2019

was $(2.0) million, or $(0.12) per share, compared with a net loss of $(1.7) million, or $(0.12) per share, for the first half

Use of Non-GAAP Financial Information

This press release contains supplemental

financial information determined by methods other than in accordance with accounting principles generally accepted in the United

States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of performance.

Adjusted EBITDA should not be considered a substitute for GAAP basis measures nor should it be viewed as a substitute for operating

results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact

of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental information

that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not

formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a

complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some

investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability.

A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

SENSUS HEALTHCARE, INC.

GAAP TO NON-GAAP RECONCILIATION

Conference Call and Webcast

The Company will host an investment community

conference call today beginning at 4:30 p.m. Eastern time, during which management will discuss financial results for the 2019

second quarter, provide a business update and answer questions. To access the conference call, the dial-in numbers are 888-567-1603

(U.S. and Canada Toll Free) or 862-298-0702 (International). Please direct the operator to be connected to the Sensus Healthcare

conference call. The call will be webcast live and can be accessed at the following link, which also may be found in the Investor

Relations section of the Company's website at www.sensushealthcare.com.

Following the conclusion of the conference

call, a replay will be available and can be accessed by dialing 888-539-4649 (U.S. and Canada Toll Free) or 754-333-7735 (International).

At the system prompt, enter the replay code 148129 followed by the # sign. An archived webcast of the call will also be available

in the Investor Relations section of the Company's website for a period of time.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device

company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and

non-oncological conditions. The Sculptura robotic radiation oncology system provides targeted intraoperative triple-modulated

radiotherapy (IORT) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting to treat patients undergoing

cancer treatment during surgery, or at the tumor site, with a single dose. Sensus also offers its proprietary low-energy X-ray

technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development,

to treat non-melanoma skin cancers and keloids with its SRT-100 , SRT-100+ and SRT-100 Vision systems. With

its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of

life of patients around the world.

For more information, visit www.sensushealthcare.com.

Forward-Looking Statements